MELBOURNE, Australia, March 29, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company’s Chief Executive Officer,James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company’s future plans for growth. The meetings will be conducted at the headquarters of Consulting for Strategic Growth 1 (CFSG1) Ltd.
“I am pleased to have this opportunity to meet with Institutional investors and update them on what is an exciting period for the Company,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Prior to the roadshow, we expect to complete our Scientific Advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), where we have put in a lot of work over the past few months to transition our lead product, PRP, into formal preclinical development and early stage patient trials. There are also other activities which we intend to undertake, such as initiating preliminary partnering discussions for PRP, expanding the Company’s R&D programs and a potential up-listing to a national exchange. All of these activities could really help establish future growth and create long term value for our shareholders.”
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over$12 billion by 2020.
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.